0001455365--12-31 2025 Q1 0 0 59854877 61974755 P36M P36M P3Y P4Y P1Y P1Y false 0001455365 us-gaap:AdditionalPaidInCapitalMember cgtx:AtMarketOfferingMember 2025-01-01 2025-03-31 0001455365 us-gaap:AdditionalPaidInCapitalMember cgtx:FollowOnPublicOfferingMember 2024-01-01 2024-03-31 0001455365 us-gaap:AdditionalPaidInCapitalMember cgtx:AtMarketOfferingMember 2024-01-01 2024-03-31 0001455365 us-gaap:CommonStockMember cgtx:AtMarketOfferingMember 2025-01-01 2025-03-31 0001455365 us-gaap:CommonStockMember cgtx:FollowOnPublicOfferingMember 2024-01-01 2024-03-31 0001455365 us-gaap:CommonStockMember cgtx:AtMarketOfferingMember 2024-01-01 2024-03-31 0001455365 us-gaap:RetainedEarningsMember 2025-03-31 0001455365 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001455365 us-gaap:RetainedEarningsMember 2024-12-31 0001455365 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001455365 us-gaap:RetainedEarningsMember 2024-03-31 0001455365 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001455365 us-gaap:RetainedEarningsMember 2023-12-31 0001455365 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001455365 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001455365 us-gaap:OtherCurrentLiabilitiesMember cgtx:InsurancePremiumFinancingAgreement2Member 2025-03-31 0001455365 us-gaap:OtherCurrentLiabilitiesMember cgtx:InsurancePremiumFinancingAgreement2Member 2024-12-31 0001455365 us-gaap:CommonStockMember 2025-03-31 0001455365 us-gaap:CommonStockMember 2024-12-31 0001455365 us-gaap:CommonStockMember 2024-03-31 0001455365 us-gaap:CommonStockMember 2023-12-31 0001455365 cgtx:EquityIncentivePlan2021Member 2025-01-01 2025-03-31 0001455365 cgtx:EquityIncentivePlan2021Member 2024-12-31 2024-12-31 0001455365 cgtx:EmployeeStockPurchasePlanMember 2025-03-31 0001455365 cgtx:AmendedAndRestatedEquityIncentivePlan2017Member 2017-09-15 0001455365 cgtx:EmployeeStockPurchasePlanMember 2025-01-01 2025-03-31 0001455365 srt:MinimumMember 2024-01-01 2024-03-31 0001455365 srt:MaximumMember 2024-01-01 2024-03-31 0001455365 us-gaap:RestrictedStockUnitsRSUMember 2025-03-31 0001455365 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001455365 cgtx:RestrictedStockUnitsTimeBasedVestingMember cgtx:ShareBasedPaymentArrangementEmployeeNonEmployeeNonEmployeeDirectorMember 2025-01-01 2025-03-31 0001455365 cgtx:RestrictedStockUnitsTimeBasedVestingMember cgtx:ShareBasedPaymentArrangementEmployeeNonEmployeeNonEmployeeDirectorMember 2024-01-01 2024-03-31 0001455365 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2025-01-01 2025-03-31 0001455365 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2025-01-01 2025-03-31 0001455365 cgtx:RestrictedStockUnitsTimeBasedVestingMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2025-01-01 2025-03-31 0001455365 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2025-01-01 2025-03-31 0001455365 cgtx:NonEmployeeDirectorMember 2025-01-01 2025-03-31 0001455365 cgtx:RestrictedStockUnitsTimeBasedVestingMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-01-01 2024-03-31 0001455365 cgtx:UnderwritingAgreementWithTitanPartnersGroupLlcMember 2024-03-14 0001455365 cgtx:AtMarketOfferingMember 2024-01-01 2024-03-31 0001455365 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001455365 2024-01-01 2024-12-31 0001455365 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001455365 cgtx:PerformanceBasedStockOptionsMember 2025-03-31 0001455365 cgtx:PerformanceBasedStockOptionsMember 2025-01-01 2025-03-31 0001455365 cgtx:InsurancePremiumFinancingAgreement2Member 2024-10-01 2024-10-31 0001455365 cgtx:InsurancePremiumFinancingAgreementMember 2023-11-01 2024-10-31 0001455365 cgtx:InsurancePremiumFinancingAgreement2Member 2024-10-31 0001455365 cgtx:InsurancePremiumFinancingAgreementMember 2023-10-31 0001455365 2024-03-31 0001455365 2023-12-31 0001455365 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2025-03-31 0001455365 us-gaap:MoneyMarketFundsMember 2025-03-31 0001455365 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0001455365 us-gaap:MoneyMarketFundsMember 2024-12-31 0001455365 us-gaap:FairValueInputsLevel1Member 2025-03-31 0001455365 us-gaap:FairValueInputsLevel1Member 2024-12-31 0001455365 us-gaap:StockOptionMember 2025-01-01 2025-03-31 0001455365 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0001455365 us-gaap:StockOptionMember 2024-01-01 2024-03-31 0001455365 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001455365 us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-03-31 0001455365 us-gaap:GeneralAndAdministrativeExpenseMember 2025-01-01 2025-03-31 0001455365 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001455365 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0001455365 cgtx:FollowOnPublicOfferingMember 2024-01-01 2024-03-31 0001455365 2025-05-05 0001455365 cgtx:UnderwritingAgreementWithTitanPartnersGroupLlcMember 2024-03-14 2024-03-28 0001455365 cgtx:UnderwritingAgreementWithTitanPartnersGroupLlcMember 2024-03-28 2024-03-28 0001455365 cgtx:UnderwritingAgreementWithTitanPartnersGroupLlcMember 2024-03-14 2024-03-14 0001455365 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001455365 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001455365 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001455365 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001455365 cgtx:AtMarketOfferingMember 2025-03-31 0001455365 cgtx:EquityIncentivePlan2021Member 2025-03-31 0001455365 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0001455365 cgtx:LifeScienceSegmentMember 2025-01-01 2025-03-31 0001455365 cgtx:LifeScienceSegmentMember 2024-01-01 2024-03-31 0001455365 cgtx:LincolnParkCapitalFundLlcMember cgtx:EquityLineFinancingMember 2025-01-01 2025-03-31 0001455365 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001455365 cgtx:AtMarketOfferingMember 2025-01-01 2025-03-31 0001455365 cgtx:LincolnParkCapitalFundLlcMember cgtx:EquityLineFinancingMember 2023-03-10 2023-03-10 0001455365 cgtx:CantorFitzgeraldAndCoAndBRileySecuritiesIncMember cgtx:AtMarketOfferingMember 2022-12-23 2022-12-23 0001455365 cgtx:AtMarketOfferingMember 2022-12-23 2022-12-23 0001455365 cgtx:AtMarketOfferingMember 2022-12-23 0001455365 2022-12-23 0001455365 2025-01-01 2025-03-31 0001455365 2024-01-01 2024-03-31 0001455365 cgtx:EquityIncentivePlan2021Member 2025-01-01 0001455365 2025-03-31 0001455365 2024-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure cgtx:segment

Table of Contents

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2025

or

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-40886

Cognition Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

​

​ | ​
Delaware | 13-4365359
(State or other jurisdiction of | (I.R.S. Employer
incorporation or organization) | Identification Number)
​ | ​
​ | ​
2500 Westchester Ave. Purchase, NY 10577 | 10577
(Address of Principal Executive Offices) ​ | (Zip Code)

​

(412) 481-2210

(Registrant’s telephone number, including area code)

​

Securities registered pursuant to Section 12(b) of the Act:

​

​ | ​ | ​ | ​ | ​
Title of Each Class |  | Trading symbol |  | Name of Exchange on which registered
Common Stock, par value $0.001 per share | ​ | CGTX | ​ | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

​

​ ​ ​ | ​ | ​ | ​
​ | ​ | ​ | ​
Large accelerated filer | ☐ | Accelerated filer | ☐
Non-accelerated filer | ☒ | Smaller reporting company | ☒
​ | ​ | Emerging growth company | ☒

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 5, 2025, there were 61,993,046 shares of the registrant’s common stock issued and outstanding.

​

​

Table of Contents

TABLE OF CONTENTS

​

​ | ​ | ​ | ​ | ​
​ |  | ​ |  | Page
--- | --- | --- | --- | ---
​ | ​ | ​ | ​ | ​
Cautionary Note on Forward-Looking Statements | ​ | 3
​ | ​ | ​ | ​ | ​
Part I. | ​ | Financial Information | ​ | 5
​ | ​ | ​ | ​ | ​
Item 1. | ​ | Financial Statements (unaudited) | ​ | 5
​ | ​ | ​ | ​ | ​
​ | ​ | Consolidated Balance Sheets as of March 31, 2025 (unaudited) and December 31, 2024 | ​ | 5
​ | ​ | ​ | ​ | ​
​ | ​ | Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2025 and 2024 (unaudited) | ​ | 6
​ | ​ | ​ | ​ | ​
​ | ​ | Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2025 and 2024 (unaudited) | ​ | 7
​ | ​ | ​ | ​ | ​
​ | ​ | Consolidated Statements of Cash Flows for the three months ended March 31, 2025 and 2024 (unaudited) | ​ | 8
​ | ​ | ​ | ​ | ​
​ | ​ | Notes to Consolidated Financial Statements (unaudited) | ​ | 9
​ | ​ | ​ | ​ | ​
Item 2. | ​ | Management’s Discussion and Analysis of Financial Condition and Results of Operations | ​ | 21
​ | ​ | ​ | ​ | ​
Item 3. | ​ | Quantitative and Qualitative Disclosures about Market Risk | ​ | 31
​ | ​ | ​ | ​ | ​
Item 4. | ​ | Controls and Procedures | ​ | 31
​ | ​ | ​ | ​ | ​
Part II. | ​ | Other Information | ​ | 33
​ | ​ | ​ | ​ | ​
Item 1. | ​ | Legal Proceedings | ​ | 33
​ | ​ | ​ | ​ | ​
Item 1A. | ​ | Risk Factors | ​ | 33
​ | ​ | ​ | ​ | ​
Item 2. | ​ | Unregistered Sales of Equity Securities and Use of Proceeds | ​ | 34
​ | ​ | ​ | ​ | ​
Item 3. | ​ | Defaults Upon Senior Securities | ​ | 34
​ | ​ | ​ | ​ | ​
Item 4. | ​ | Mine Safety Disclosures | ​ | 34
​ | ​ | ​ | ​ | ​
Item 5. | ​ | Other Information | ​ | 34
​ | ​ | ​ | ​ | ​
Item 6. | ​ | Exhibits | ​ | 35
​ | ​ | ​ | ​ | ​
Signatures | ​ | ​ | ​ | 36

​

2

Table of Contents

Cautionary Note on Forward-Looking Statements

​

This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements concerning our business, operations and financial performance, as well as our plans, objectives and expectations for our business operations and financial performance and condition. All statements other than statements of historical or current facts included in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. In addition, statements including “we believe” or similar phrases reflect our beliefs and opinions on the relevant subject. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed in, or implied by these, forward-looking statements and therefore, you should not unduly rely on such statements. These risks and uncertainties include, but not limited to:

| ● | our ability to raise additional capital to fund our operations and continue the development of our current and future product candidates;

| ● | our ability to continue as a going concern for the next twelve months;

| ● | our ability to maintain the listing of our common stock on the Nasdaq Capital Market;

| ● | our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;

| ● | the clinical nature of our business and our ability to successfully and in a timely manner advance our current and future product candidates through our ongoing and future clinical trials, preclinical studies and development activities;

| ● | the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates;

| ● | our ability to generate revenue from future product sales and our ability to achieve and maintain profitability;

| ● | the accuracy of our projections and estimates regarding our expenses, capital requirements, cash utilization, and need for additional financing;

| ● | the expected uses of our existing cash and cash equivalents and the sufficiency of such resources to fund our planned operations;

| ● | the extent to which health epidemics and other outbreaks of communicable diseases, geopolitical turmoil, including the ongoing global and regional conflicts or increased trade restrictions between the United States, Russia, China, and other countries, social unrest, political instability, terrorism, or other acts of war could ultimately impact our business, including our ongoing and future clinical trials, preclinical studies and development activities;

| ● | our dependence on the success of zervimesine (CT1812), our lead product candidate;

| ● | the novelty of our approach to targeting the σ-2 (sigma-2) receptor (“S2R”) complex to treat age-related degenerative diseases and disorders, and the challenges we will face due to the novel nature of such approach;

| ● | the success of competing therapies that are or become available;

3

Table of Contents

| ● | the initiation, progress, success, cost, and timing of our ongoing and future clinical trials, preclinical studies and development activities;

| ● | our ability to obtain and maintain regulatory clearance of CT1812 for clinical trials under investigational new drug, or IND, applications and any future IND applications for any of our other product candidates;

| ● | the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers;

| ● | our ability to attract and retain strategic collaborators with development, regulatory, and commercialization expertise;

| ● | our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved;

| ● | the size and growth of the potential markets for our product candidates and our ability to serve those markets;

| ● | regulatory developments and approval pathways in the United States and foreign countries for our product candidates;

| ● | the potential scope and value of our intellectual property and proprietary rights;

| ● | our ability, and the ability of any future licensors, to obtain, maintain, defend, and enforce intellectual property and proprietary rights protecting our product candidates, and our ability to develop and commercialize our product candidates without infringing, misappropriating, or otherwise violating the intellectual property or proprietary rights of third parties;

| ● | risks associated with global political changes and global economic conditions, including inflation, tariffs, or uncertainty caused by political violence and unrest, including ongoing global and regional conflicts;

| ● | developments relating to our competitors and our industry; and

| ● | other risk and uncertainties, including those described in Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K (“Annual Report”) filed with the SEC on March 20, 2025.

You should refer to the “Risk Factors” section of our Annual Report for the year ended December 31, 2024 for a discussion of material factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Quarterly Report on Form 10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. We intend the forward-looking statements contained in this Quarterly Report to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Exchange Act, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

4

Table of Contents

PART I – FINANCIAL INFORMATION

Item 1.Financial Statements

​

COGNITION THERAPEUTICS, INC.

CONSOLIDATED BALANCE SHEETS

(unaudited)

(in thousands, except share and per share amounts)

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | As of
​ | ​ | March 31, 2025 | ​ | December 31, 2024
​ |  | (unaudited) | ​ | ​
Assets |  | ​ |  | ​ | ​ |
Current assets: |  | ​ |  | ​ | ​ |
Cash and cash equivalents | ​ | $ | 16,428 | ​ | $ | 25,009
Grant receivables | ​ |  | 4,778 | ​ |  | 2,686
Prepaid expenses and other current assets | ​ |  | 1,660 | ​ |  | 1,860
Total current assets | ​ |  | 22,866 | ​ |  | 29,555
Property and equipment, net | ​ |  | 190 | ​ |  | 181
Right-of-use assets, operating leases | ​ | ​ | 444 | ​ | ​ | 498
Total assets | ​ | $ | 23,500 | ​ | $ | 30,234
Liabilities and Stockholders’ Equity | ​ |  |  | ​ |  |
Current liabilities: | ​ |  |  | ​ |  |
Accounts payable | ​ | $ | 1,821 | ​ | $ | 1,984
Accrued expenses | ​ |  | 7,708 | ​ |  | 7,620
Deferred grant income, current | ​ | ​ | 1,066 | ​ | ​ | 1,066
Operating lease liabilities, current | ​ | ​ | 194 | ​ | ​ | 193
Other current liabilities | ​ |  | 161 | ​ |  | 279
Total current liabilities | ​ |  | 10,950 | ​ |  | 11,142
Operating lease liabilities, non-current | ​ |  | 280 | ​ |  | 342
Total liabilities | ​ |  | 11,230 | ​ |  | 11,484
Commitments and contingencies (Note 6) | ​ |  |  | ​ |  |
Stockholders’ equity: | ​ |  |  | ​ |  |
Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2025 and December 31, 2024 | ​ | ​ | — | ​ | ​ | —
Common stock, $0.001 par value, 250,000,000 shares authorized; 61,974,755 and 59,854,877 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | ​ |  | 62 | ​ |  | 60
Additional paid-in capital | ​ |  | 195,848 | ​ |  | 193,850
Accumulated deficit | ​ |  | (183,640) | ​ |  | (175,160)
Total stockholders’ equity | ​ |  | 12,270 | ​ |  | 18,750
Total liabilities and stockholders’ equity | ​ | $ | 23,500 | ​ | $ | 30,234

​

The accompanying notes are an integral part of these consolidated financial statements.

5

Table of Contents

COGNITION THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited)

(in thousands, except share and per share amounts)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, | ​ | ​
​ |  | 2025 |  | 2024 |  | ​
Operating Expenses: |  | ​ |  |  | ​ |  | ​ | ​
Research and development | ​ | $ | 10,786 | ​ | $ | 10,553 | ​ | ​
General and administrative | ​ |  | 2,989 | ​ |  | 3,549 | ​ | ​
Total operating expenses | ​ |  | 13,775 | ​ |  | 14,102 | ​ | ​
Loss from operations | ​ |  | (13,775) | ​ |  | (14,102) | ​ | ​
Other income (expense): | ​ |  |  | ​ |  |  | ​ | ​
Grant income | ​ |  | 5,086 | ​ |  | 4,912 | ​ | ​
Other income, net | ​ |  | 214 | ​ |  | 244 | ​ | ​
Interest expense | ​ |  | (5) | ​ |  | (10) | ​ | ​
Loss on currency translation from liquidation of subsidiary | ​ | ​ | — | ​ | ​ | (195) | ​ | ​
Total other income, net | ​ |  | 5,295 | ​ |  | 4,951 | ​ | ​
Net loss | ​ | $ | (8,480) | ​ | $ | (9,151) | ​ | ​
Foreign currency translation adjustment, including reclassifications | ​ |  | — | ​ |  | 195 | ​ | ​
Total comprehensive loss | ​ | $ | (8,480) | ​ | $ | (8,956) | ​ | ​
Net loss per share: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic | ​ | $ | (0.14) | ​ | $ | (0.27) | ​ | ​
Diluted | ​ | $ | (0.14) | ​ | $ | (0.27) | ​ | ​
Weighted-average common shares outstanding: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic | ​ | ​ | 61,828,149 | ​ | ​ | 33,735,269 | ​ | ​
Diluted | ​ | ​ | 61,828,149 | ​ | ​ | 33,735,269 | ​ | ​

​

The accompanying notes are an integral part of these consolidated financial statements.

​

​

6

Table of Contents

COGNITION THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(unaudited)

(in thousands, except share amounts)

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | ​ | ​ | ​ | Other | ​ | Total
​ | ​ | Common Stock | ​ | Paid-in | ​ | Accumulated | ​ | Comprehensive | ​ | Stockholders’
​ |  | Shares |  | Amount |  | Capital |  | Deficit |  | (Loss) Gain |  | Equity
Balances as of December 31, 2023 |  | 32,165,478 | ​ | $ | 32 | ​ | $ | 165,826 | ​ | $ | (141,189) | ​ | $ | (195) | ​ | $ | 24,474
Issuance of common stock in follow-on public offering, net of discounts and issuance costs of $1,329 |  | 7,557,142 | ​ | ​ | 8 | ​ | ​ | 11,888 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 11,896
Issuance of common stock under the at-the-market (ATM) sales agreement, net | ​ | 191,273 | ​ | ​ | — | ​ | ​ | 381 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 381
Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes | ​ | 71,973 | ​ | ​ | — | ​ | ​ | (106) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (106)
Equity-based compensation |  | — | ​ | ​ | — | ​ | ​ | 1,171 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,171
Reclassification adjustment of foreign currency translation included in net loss for liquidation of subsidiary | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 195 | ​ | ​ | 195
Net loss | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (9,151) | ​ | ​ | — | ​ | ​ | (9,151)
Balances as of March 31, 2024 | ​ | 39,985,866 | ​ | $ | 40 | ​ | $ | 179,160 | ​ | $ | (150,340) | ​ | $ | — | ​ | $ | 28,860

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | ​ | ​ | ​ | Other | ​ | Total
​ | ​ | Common Stock | ​ | Paid-in | ​ | Accumulated | ​ | Comprehensive | ​ | Stockholders’
​ |  | Shares |  | Amount |  | Capital |  | Deficit |  | (Loss) Gain |  | Equity
Balances as of December 31, 2024 |  | 59,854,877 | ​ | $ | 60 | ​ | $ | 193,850 | ​ | $ | (175,160) | ​ | $ | — | ​ | $ | 18,750
Issuance of common stock under the at-the-market (ATM) sales agreement, net | ​ | 2,004,729 | ​ | ​ | 2 | ​ | ​ | 1,458 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,460
Issuance of common stock upon vesting of RSUs, net of shares withheld for employee taxes | ​ | 115,149 | ​ | ​ | — | ​ | ​ | (46) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (46)
Equity-based compensation | ​ | — | ​ | ​ | — | ​ | ​ | 586 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 586
Net loss | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (8,480) | ​ | ​ | — | ​ | ​ | (8,480)
Balances as of March 31, 2025 | ​ | 61,974,755 | ​ | $ | 62 | ​ | $ | 195,848 | ​ | $ | (183,640) | ​ | $ | — | ​ | $ | 12,270

​

​

​

​

​

The accompanying notes are an integral part of these consolidated financial statements.

​

​

7

Table of Contents

COGNITION THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in thousands)

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31,
​ |  | 2025 |  | 2024
Cash flows from operating activities: |  | ​ |  |  | ​ |
Net loss | ​ | $ | (8,480) | ​ | $ | (9,151)
Adjustments to reconcile net loss to net cash used in operating activities: | ​ |  |  | ​ |  |
Depreciation and amortization | ​ |  | (9) | ​ | ​ | 27
Equity-based compensation | ​ |  | 586 | ​ | ​ | 1,171
Amortization of right-of-use assets | ​ | ​ | 54 | ​ | ​ | 31
Loss on currency translation from liquidation of subsidiary | ​ | ​ | — | ​ | ​ | 195
Changes in operating assets and liabilities: | ​ |  | ​ | ​ | ​ | ​
Grant receivables | ​ |  | (2,092) | ​ | ​ | 420
Prepaid expenses and other assets | ​ |  | 200 | ​ | ​ | 583
Accounts payable and accrued expenses | ​ |  | (75) | ​ | ​ | (377)
Deferred grant income and other liabilities | ​ | ​ | — | ​ | ​ | (117)
Operating lease liabilities | ​ |  | (61) | ​ | ​ | (26)
Net cash used in operating activities | ​ |  | (9,877) | ​ |  | (7,244)
Cash flows from investing activities: | ​ |  | ​ | ​ |  | ​
Payments for property and equipment | ​ |  | — | ​ | ​ | —
Net cash used in investing activities | ​ |  | — | ​ |  | —
Cash flows from financing activities: | ​ |  |  | ​ |  |
Proceeds from issuance of common stock under the ATM sales agreement, net | ​ |  | 1,460 | ​ | ​ | 381
Proceeds from issuance of common stock in follow-on public offering, net | ​ | ​ | — | ​ | ​ | 11,896
Payment of employee withholding taxes on vested restricted stock units | ​ | ​ | (46) | ​ | ​ | (106)
Payments on loan payable | ​ | ​ | (118) | ​ | ​ | (178)
Net cash provided by financing activities | ​ |  | 1,296 | ​ |  | 11,993
Net (decrease) increase in cash and cash equivalents | ​ |  | (8,581) | ​ |  | 4,749
Cash and cash equivalents | ​ | ​ | ​ | ​ | ​ | ​
Cash and cash equivalents – beginning of period | ​ |  | 25,009 | ​ |  | 29,922
Cash and cash equivalents – end of period | ​ | $ | 16,428 | ​ | $ | 34,671

​

The accompanying notes are an integral part of these consolidated financial statements.

​

8

Table of Contents

Cognition Therapeutics, Inc.

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share amounts)

1. Description of Business and Financial Condition

Cognition Therapeutics, Inc. (the “Company”) was incorporated as a Delaware corporation on August 21, 2007. The Company is a biopharmaceutical company developing disease modifying therapies targeting age-related degenerative diseases and disorders of the central nervous system (“CNS”) and retina. The Company’s pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways specifically associated with neurodegenerative diseases. The Company was founded on the unique combination of biological expertise around these targets, including proprietary assays that emphasize functional responses, and proprietary medicinal chemistry intended to produce novel, high-quality small-molecule drug candidates.

On December 23, 2022, the Company filed a Registration Statement on Form S-3 (File No. 333-268992) (the “Shelf”) with the Securities and Exchange Commission (“SEC”) in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $200,000 in aggregate. The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with Cantor Fitzgerald & Co. and B. Riley Securities, Inc. (the “Sales Agents”) providing for the offering, issuance and sale by the Company of up to $40,000 of its common stock from time to time in “at-the-market” offerings under the Shelf (the “ATM”). During the three months ended March 31, 2025, the Company sold 2,004,729 shares of its common stock pursuant to the ATM for gross proceeds of approximately $1,505. Please refer to Note 7 – Stockholders’ Equity for further details.

On March 10, 2023, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”) for an equity line financing (the “Purchase Agreement”). The Purchase Agreement provides that, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to $35,000 of shares of common stock in the Company’s sole discretion, over a 36-month period commencing on March 10, 2023. The Company filed a prospectus supplement to its Registration Statement on Form S-3 (File No. 333-268992) covering the resale of shares of common stock that may be issued under the Purchase Agreement. As part of the Purchase Agreement, the Company issued 189,856 shares of its common stock as consideration for Lincoln Park’s commitment to purchase shares of common stock under the Purchase Agreement. During the three months ended March 31, 2025, the Company did not sell any shares of common stock to Lincoln Park. As of March 31, 2025, $34,795 was available to draw pursuant to the Purchase Agreement. Please refer to Note 7 – Stockholders’ Equity for further details.

Liquidity and Going Concern

The Company’s Consolidated Financial Statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since inception, including net losses of $8,480 for the three months ended March 31, 2025 and $33,971 for the year ended December 31, 2024. As of March 31, 2025, the Company held cash and cash equivalents of $16,428 compared to $25,009 of cash and cash equivalents as of December 31, 2024. The Company has incurred losses and negative cash flows from operations and has an accumulated deficit of $183,640 as of March 31, 2025. The Company expects to continue to incur losses for the foreseeable future.

As of May 7, 2025, the date of issuance of these Consolidated Financial Statements, the Company believes that its cash and cash equivalents as of March 31, 2025 is not sufficient to fund operations for the period through one year after the date of this filing and therefore substantial doubt exists about the Company’s ability to continue as a going concern.

To execute its business plans, the Company will need substantial funding to support its continuing operations and pursue its growth strategy. Until such time that the Company can generate significant revenue from product sales, if ever,

9

Table of Contents

the Company expects to finance its operations through the sale of common stock in public offerings and/or private placements, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or abandon its product development programs, which could have a material adverse effect on its business prospects.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements as of March 31, 2025, and for the three months ended March 31, 2025 and 2024, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying unaudited interim consolidated financial statements contain all adjustments that are necessary to present fairly the Company’s financial position as of March 31, 2025, the statements of operations and comprehensive loss and stockholders’ equity for the three months ended March 31, 2025 and 2024, and cash flows for the three months ended March 31, 2025 and 2024. Such adjustments are of a normal and recurring nature. The results for the three months ended March 31, 2025 are not necessarily indicative of the results for the year ending December 31, 2025, or for any future period. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2024, and the notes thereto, which are included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 20, 2025.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents consist primarily of interest-bearing deposits at various financial institutions and money markets. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.

Grant Receivables

Grant receivables relate to outstanding amounts due for reimbursable expenditures of awarded grants issued by the National Institute of Aging (“NIA”), a division of the National Institute of Health (“NIH”), and are carried at their estimated collectible amounts. The Company expects all receivables to be collectible, and accordingly, there is no allowance for doubtful accounts required on these grant receivables.

Grant Income

The Company generates grant income through grants from government and other (non-government) organizations. Grant income is recognized in other income (expense) in the period in which the reimbursable research and development services are incurred and the right to payment is realized. Deferred grant income represents grant proceeds received by the Company prior to the period in which the reimbursable research and development services are incurred. For the three months ended March 31, 2025 and 2024, the Company generated grant income of $5,086 and $4,912, respectively, primarily from reimbursements from the NIA for aging research. Deferred grant income as of March 31, 2025 and December 31, 2024 was $1,066.

10

Table of Contents

The grants awarded relate to agreed-upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to contract research organizations (“CROs”), research institutions and/or consortiums involved in the grants, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which the Company is reimbursed for its eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH’s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. While these NIH grants do not contain payback provisions, the NIH or other government agency may review the Company’s performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIH grant. If any of the expenditures are found to be unallowable or allocated improperly or if the Company has otherwise violated terms of such NIH grant, the expenditures may not be reimbursed and/or the Company may be required to repay funds already disbursed. To date, the Company has not been found to have breached the terms of any NIH grant. As of March 31, 2025, the Company has been awarded grants with project periods that extend through May 31, 2027, subject to extension.

Research and Development Costs

The Company is involved in research and development of treatments for a variety of diseases related to the central nervous system, with a focus on Alzheimer’s disease, dementia with Lewy bodies, and geographic atrophy (“GA”) secondary to dry age-related macular degeneration. Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation, and benefits for employees, third-party license fees and other operational costs related to its research and development activities, including allocated facility-related expenses and external costs of outside vendors, including CROs, and other direct and indirect costs. Non-refundable research and development costs are deferred and expensed as the related goods are delivered or services are performed. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain research and development activities are recognized based on the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in the consolidated financial statements as prepaid expenses or as accrued research and development expenses.

Equity-based Compensation

Following the provisions of ASC 718, Compensation — Stock Compensation, the Company recognizes compensation expense for equity-based grants using the straight-line attribution method, in which the expense is recognized ratably over the requisite service period within operating expenses based on the grant date fair value. The Company also has granted awards subject to performance-based vesting. The Company recognizes compensation expense for these awards commencing in the period in which the vesting condition becomes probable of achievement. The grant date fair value of stock options are estimated on the date of grant using the Black-Scholes option pricing model. Forfeitures are recognized in the period in which they occur.

Black-Scholes requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to a lack of sufficient public market data for the Company’s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method to calculate the expected term for stock options granted to employees whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. Refer to Note 8 – Equity-based Compensation for additional information.

11

Table of Contents

Concentration of Credit Risk

The Company’s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.

Fair Value of Financial Instruments

The Company applies ASC 820, Fair Value Measurement (“ASC 820”), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company’s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.

The carrying value of the Company’s cash and cash equivalents, grants receivable, prepaid expense, other receivables, other assets, accounts payable, accrued expenses and other liabilities approximate fair value because of the short-term maturity of these financial instruments.

The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:

| ● | Level 1—  Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.

| ● | Level 2—  Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.

| ● | Level 3—  Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.

Net Loss Per Share

Basic net loss per share is computed by dividing the net loss per share by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.

12

Table of Contents

Segments

The Company has determined that it operates and manages one operating segment, which is the business of development of clinical and preclinical product candidates for neurodegenerative disorders, such as Alzheimer’s disease (“AD”) and dementia with Lewy bodies (“DLB”). The Company’s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources. Refer to Note 10 – Segment Reporting for more information.

Emerging Growth Company Status

The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a) no longer an emerging growth company or (b) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

Recent Accounting Pronouncements

Adopted

In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which enhances segment disclosures and requires additional disclosures of segment expenses. This ASU is effective for annual periods in fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. We adopted this ASU for the annual period ended December 31, 2024 and the amendments have been applied retrospectively to all prior periods presented in the financial statements by expanding the disclosure of expenses included in our segment measures of profitability. Refer to Note 10 – Segment Reporting for more information.

In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (“ASU 2023-09”). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity’s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity’s unrecognized tax benefit and the cumulative amount of certain temporary differences. The Company adopted this ASU for the annual period beginning January 1, 2025.

Not Yet Adopted

In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements (“ASU 2023-06”), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.

13

Table of Contents

Income Taxes

In accordance with ASC 270, Interim Reporting, and ASC 740, Income Taxes, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate, apply that rate in providing for income taxes on a current year-to-date (interim period) basis, and include the tax impact for discrete items within the interim period. The Company maintains a full valuation allowance against all deferred tax assets as of March 31, 2025 and December 31, 2024, as management has determined that it is not more likely than not that the Company will realize these future tax benefits. As of March 31, 2025 and December 31, 2024, the Company had no uncertain tax positions.

​

3. Financial Instruments and Fair Value Measurements

Financial assets and liabilities measured at fair value are summarized below:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | As of March 31, 2025
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Significant | ​ | ​ | ​
​ | ​ | Quoted Priced in | ​ | Significant Other | ​ | Unobservable | ​ | ​ | ​
​ | ​ | Active Markets | ​ | Observable Inputs | ​ | Inputs | ​ | ​ | ​
​ |  | (Level 1) |  | (Level 2) |  | (Level 3) |  | Total
Assets: |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
Money market funds | ​ | $ | 16,179 | ​ | $ | — | ​ | $ | — | ​ | $ | 16,179
Total assets | ​ | $ | 16,179 | ​ | $ | — | ​ | $ | — | ​ | $ | 16,179

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | As of December 31, 2024
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Significant | ​ | ​ | ​
​ | ​ | Quoted Priced in | ​ | Significant Other | ​ | Unobservable | ​ | ​ | ​
​ | ​ | Active Markets | ​ | Observable Inputs | ​ | Inputs | ​ | ​ | ​
​ |  | (Level 1) |  | (Level 2) |  | (Level 3) |  | Total
Assets: |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
Money market funds | ​ | $ | 23,999 | ​ | $ | — | ​ | $ | — | ​ | $ | 23,999
Total assets | ​ | $ | 23,999 | ​ | $ | — | ​ | $ | — | ​ | $ | 23,999

​

​

4. Accrued Expenses

Accrued expense consists of the following:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | As of | ​
​ |  | March 31, 2025 |  | December 31, 2024 | ​
Employee compensation, benefits, and related accruals | ​ | $ | 600 | ​ | $ | 1,526 | ​
Research and development costs | ​ |  | 6,837 | ​ |  | 5,654 | ​
Professional fees and other accruals | ​ |  | 271 | ​ |  | 440 | ​
Total | ​ | $ | 7,708 | ​ | $ | 7,620 | ​

​

​

​

5. Other Current Liabilities

In October 2023, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $721 of certain premiums at a 8.65% annual interest rate. Total payments of approximately $62, including interest and principal, are due monthly from November 2023 through October 2024. The outstanding principal of the loan was paid off in 2024.

14

Table of Contents

In October 2024, the Company entered into an insurance premium financing agreement with a lender. Under the agreement, the Company financed $356 of certain premiums at a 8.65% annual interest rate. Total payments of approximately $41, including interest and principal, are due monthly from November 2024 through July 2025. As of March 31, 2025 and December 31, 2024, the outstanding principal of the loan was $161 and $279, respectively, and is included in other current liabilities on the consolidated balance sheet.

6. Commitments and Contingencies

Operating Leases

Amounts reported in the consolidated balance sheets for leases where the Company is the lessee as of March 31, 2025 were as follows, in thousands:

​

​ | ​ | ​ | ​ | ​ | ​
​ | As of
​ | March 31, 2025 | ​ | December 31, 2024
Assets |  | ​ | ​ |  | ​
Operating lease assets | $ | 444 | ​ | $ | 498
Total operating lease assets | $ | 444 | ​ | $ | 498
Liabilities | ​ | ​ | ​ | ​ | ​
Current: | ​ | ​ | ​ | ​ | ​
Operating lease liabilities | $ | 194 | ​ | $ | 193
Non-current: | ​ | ​ | ​ | ​ | ​
Operating lease liabilities, non-current | ​ | 280 | ​ | ​ | 342
Total operating lease liabilities | $ | 474 | ​ | $ | 535

​

Operating lease costs for the three months ended March 31, 2025 and 2024 was $54 and $55, respectively.

The maturities of the operating lease liabilities and minimum lease payments as of March 31, 2025 were as follows:

​

​ | ​ | ​ | ​
For the Years Ended December 31, |  | Operating Leases
2025 (remaining) | ​ | $ | 167
2026 | ​ |  | 155
2027 | ​ |  | 87
2028 | ​ | ​ | 88
2029 | ​ | ​ | 38
Thereafter | ​ | ​ | —
Total undiscounted lease payments | ​ | $ | 535
Less: Imputed interest | ​ | ​ | (61)
Present value of operating lease liabilities | ​ | $ | 474

​

The following table summarizes the lease term and discount rate as of March 31, 2025:

​

​ | ​ | ​ | ​
​ | As of
​ | March 31, 2025 | ​ | December 31, 2024
Weighted-average remaining lease term (years) | ​ | ​ | ​
Operating leases | 3.2 | ​ | 3.3
Weighted-average discount rate | ​ | ​ | ​
Operating leases | 8.1% | ​ | 8.1%

​

Operating cash flows used for operating leases for the three months ended March 31, 2025 and 2024 was $56 and $56, respectively.

15

Table of Contents

Litigation and Contingencies

From time to time, the Company may be involved in disputes or regulatory inquiries that arise in the ordinary course of business. When the Company determines that a loss is both probable and reasonably estimable, a liability is recorded and disclosed if the amount is material to the financial statements taken as a whole. When a material loss contingency is only reasonably possible, the Company does not record a liability but instead discloses the nature and the amount of the claim and an estimate of the loss or range of loss, if such an estimate can reasonably be made.

As of March 31, 2025 and December 31, 2024, there was no litigation or contingency with at least a reasonable possibility of a material loss.

7. Stockholders’ Equity

Common and Preferred Stock

The Company is authorized to issue up to 250,000,000 shares of common stock with a par value of $0.001 per share, and 10,000,000 shares of preferred stock with a par value of $0.001 per share.

Common stockholders are entitled to dividends if and when declared by the Company’s board of directors subject to the rights of the preferred stockholders. As of March 31, 2025, no dividends on common stock had been declared by the Company.

ATM

On December 23, 2022, the Company filed a shelf registration statement on Form S-3 with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants, subscription rights, and/or units of any combination thereof of up to $200,000 in aggregate (the “Shelf”). The Shelf was declared effective on January 3, 2023 by the SEC. The Company also simultaneously entered into a sales agreement with the Sales Agents providing for the offering, issuance and sale by the Company of up to $40,000 of its common stock from time to time in ATM offerings under the Shelf. The Company sold 2,004,729 shares of common stock pursuant to the ATM during the three months ended March 31, 2025 for gross proceeds of approximately $1,505. As of March 31, 2025, there was $20,369 remaining of common stock available for sale under the ATM, subject to the limitations of General Instruction I.B.6 of Form S-3.

Lincoln Park Purchase Agreement

On March 10, 2023, the Company entered into a purchase agreement with Lincoln Park for an equity line financing. The Purchase Agreement provides that, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to $35,000 of shares of common stock in the Company’s sole discretion, over a 36-month period commencing on March 10, 2023. During the three months ended March 31, 2025, the Company did not sell any shares of common stock to Lincoln Park. As of March 31, 2025, $34,795 was available to draw pursuant to the Purchase Agreement.

March 2024 Offering

In March 2024, the Company entered into an underwriting agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC, relating to the issuance and sale by the Company of 7,557,142 shares of its common stock, which included the exercise of the underwriters’ option to purchase 985,714 additional shares of common stock, at a public offering price of $1.75 per share. The Company closed this offering on March 14, 2024 and the full exercise of the underwriters’ option to purchase 985,714 additional shares of common stock was closed on March 28, 2024. The Company received net proceeds of approximately $11,896, after deducting $1,329 of underwriting discounts and commissions and other offering related expenses payable by the Company.

16

Table of Contents

8. Equity-based Compensation

2021 Equity Incentive Plan

On October 7, 2021, the date upon which the Company’s Registration Statement on Form S-1 in connection with the IPO was declared effective, the Company’s 2021 Equity Incentive Plan (the “2021 Plan”) became effective. On the same date, the Company ceased granting awards under its 2017 Equity Incentive Plan (the “2017 Plan”). The 2021 Plan authorizes the award of both equity-based and cash-based incentive awards, including: (i) stock options (both incentive stock options and nonqualified stock options), (ii) stock appreciation rights, (iii) restricted stock awards, (iv) restricted stock units (“RSUs”), and (v) cash or other stock-based awards. Incentive stock options may be granted only to employees. All other types of awards may be issued to employees, directors, consultants, and other service providers.

As of March 31, 2025, the aggregate number of shares of common stock of the Company that may be issued under the 2021 Plan is 3,073,114. The number of shares reserved for issuance under the 2021 Plan increased automatically on January 1, 2025 pursuant to an evergreen provision therein by 2,992,743 shares, representing 5% of total common shares outstanding at December 31, 2024. The aggregate number of shares will increase each anniversary of such date prior to the termination of the 2021 Plan, equal to the lesser of (i) 5% of the Company’s shares of common stock issued and outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Company’s board of directors or the compensation committee. No more than 9,057,517 shares of common stock may be issued under the 2021 Plan through incentive stock options. Shares subject to the 2021 Plan, the 2017 Plan or the 2007 Equity Incentive Plan (the “2007 Plan” and collectively with the 2017 Plan, the “Prior Plans”) that expire, terminate or are cancelled or forfeited for any reason after the effectiveness of the 2021 Plan will be added (or added back) to the shares available for issuance under the 2021 Plan. The total number of shares underlying the Prior Plan awards that may be recycled into the 2021 Plan will not exceed 4,334,131 shares.

2017 Equity Incentive Plan

On September 15, 2017, the Company’s board of directors approved the 2017 Plan, which provides for the granting of incentive stock options, non-qualified stock options and stock awards to employees, certain consultants and directors. The board of directors, or its designated committee, has the sole authority to select the individuals to whom awards are granted and determine the terms of each award, including the number of shares and the schedule upon which the award becomes exercisable. Upon the effectiveness of the 2021 Plan, no further awards will be granted under the 2017 Plan.

The aggregate number of shares of common stock of the Company that may be issued under the 2017 Plan is 4,334,131 (taking into account shares of common stock that may become issuable pursuant to Section 3(b) of the 2017 Plan in respect of shares of common stock reserved under the Company’s Amended and Restated 2007 Equity Incentive Plan). The 2021 Plan provides for shares granted under the Prior Plans which are cancelled, forfeited, exchanged or surrendered without having been exercised shall subsequently be available for reissuance under the 2021 Plan.

Employee Stock Purchase Plan

The Company’s board of directors approved the Employee Stock Purchase Plan (the “ESPP”) prior to the closing of the IPO. Under the ESPP, the Company may provide employees and employees of the Subsidiary with an opportunity to purchase shares of the Company’s common stock at a discounted purchase price. As of March 31, 2025, a total of 209,532 shares of common stock are authorized and reserved for issuance under the ESPP.

Subject to prior approval by the board of directors in each instance, on or about January 1, 2022 and each anniversary of such date thereafter prior to the termination of the ESPP, the number of shares of common stock authorized and reserved for issuance under the ESPP will be increased by a number of shares of common stock equal to the least of (i) 1,000,000 shares of common stock, (ii) 1% of the shares of common stock outstanding on the final day of the immediately preceding calendar year, and (iii) such smaller number of shares of common stock as determined by the board of directors. Such shares of common stock may be newly issued shares, treasury shares or shares acquired on the open market. In the event that any dividend or other distribution (whether in the form of cash, our common stock, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, or

17

Table of Contents

exchange of common stock or other securities, or other change in the structure affecting common stock occurs, then in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the ESPP, the compensation committee will, in such manner as it deems equitable, adjust the number of shares and class of common stock that may be delivered under the ESPP, the purchase price per share and the number of shares covered by each outstanding option under the ESPP, and the numerical limits described above.

Stock Options

The fair value of options granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:

​

​ | ​ | ​
​ | ​ | Three Months Ended March 31,
​ |  | 2024
Expected volatility |  | 92.29%
Risk-free interest rate |  | 4.23%
Dividend yield |  | 0.00%
Expected term (years) |  | 6.10 – 6.20

​

During the three months ending March 31, 2025, there were no stock options granted.

Expected Term— The expected term represents the period that the stock-based awards are expected to be outstanding. As the Company does not have sufficient historical experience for determining the expected term of the stock option awards granted, expected term has been calculated using the simplified method.

Risk-Free Interest Rate— The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury constant maturity notes with terms approximately equal to the stock-based awards’ expected term.

Expected Volatility— Up until October 13, 2021, the Company was privately held and did not have a trading history of common stock. As such, the expected volatility was derived from the average historical stock volatilities of the common stock of several public companies within the industry that the Company considers to be comparable to our business over a period equivalent to the expected term of the stock-based awards. The Company will continue to derive expected volatility from average historical stock volatilities of industry peers until the Company has compiled a trading history of its own for a sufficient period of time.

Dividend Yield— The expected dividend yield is zero as the Company has not paid and does not anticipate paying any dividends in the foreseeable future.

Activity for options was as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Options Outstanding
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Weighted-Average
​ | ​ | ​ | ​ | ​ | ​ | Aggregate | ​ | Remaining
​ | ​ | Number of | ​ | Weighted-Average | ​ | Intrinsic Value | ​ | Contractual Life
​ |  | Options |  | Exercise Price |  | (in 000’s) |  | (In Years)
Balance, December 31, 2024 |  | 4,353,490 | ​ | $ | 4.67 |  | $ | — | ​ | 5.8
Options granted |  | — | ​ | $ | — | ​ | ​ | ​ | ​ | ​
Options exercised |  | — | ​ | $ | — | ​ | ​ | ​ | ​ | ​
Options forfeited |  | — | ​ | $ | — | ​ | ​ | ​ | ​ | ​
Options expired |  | (8,985) | ​ | $ | 1.90 | ​ | ​ | ​ | ​ | ​
Balance, March 31, 2025 |  | 4,344,505 | ​ | $ | 4.67 | ​ | $ | — | ​ | 5.5
Exercisable as of March 31, 2025 |  | 3,809,084 | ​ | $ | 4.98 | ​ | $ | — | ​ | 5.2

​

18

Table of Contents

There were no grants of stock options for the three months ended March 31, 2025. The weighted-average grant date fair value of stock options granted was $1.56 during the three months ended March 31, 2024. There were 205,000 stock options granted at an aggregate fair value of $320 for the three months ended March 31, 2024. During the three months ended March 31, 2025 and 2024, there were no stock options exercised.

Restricted Stock Units

The fair values of RSUs are based on the fair market value of the Company’s common stock on the date of grant. Each RSU represents a contingent right to receive one share of the Company’s common stock upon vesting. RSUs with time base vesting conditions for employees vest annually over three or four years on each anniversary of the Grant Date and RSUs for non-employee directors vest on the one-year anniversary of the Grant Date. RSUs with performance conditions for employees vest on the one-year anniversary of the performance achievement date, assuming continued service from the employee during that period of time.

During the three months ended March 31, 2025 and 2024, the Company granted 2,587,008 and 280,600 RSU awards, respectively, containing time based vesting conditions to employees, non-employees, and non-employee directors.

During the three months ended March 31, 2025 and 2024, the Company granted 0 and 515,600 RSU awards containing performance and time based vesting conditions to employees. The performance conditions for the RSU awards granted in 2024 were achieved in 2024 and the RSUs will vest on the one-year anniversary of the achievement of the performance condition. As of March 31, 2025, the RSU awards granted in 2024 had no remaining performance conditions.

The following table summarizes the Company’s RSU activity for the three months ended March 31, 2025:

​

​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Number of | ​ | Weighted-Average
​ | ​ | Restricted Stock Units | ​ | Grant Date Fair Value
Outstanding at December 31, 2024 | ​ | 1,172,964 | ​ | $ | 1.98
Granted | ​ | 2,587,008 | ​ | $ | 0.63
Vested | ​ | (185,626) | ​ | $ | 2.06
Forfeited | ​ | — | ​ | $ | —
Outstanding at March 31, 2025 | ​ | 3,574,346 | ​ | $ | 1.00

​

Equity-based Compensation Expense

​

The Company recorded total equity-based compensation expense in the statement of operations and comprehensive loss related to stock options and restricted stock units as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, |
​ |  | 2025 |  | 2024 |
Research and development | ​ | $ | 310 | ​ | $ | 231 | ​
General and administrative | ​ |  | 276 | ​ |  | 940 | ​
Total equity-based compensation | ​ | $ | 586 | ​ | $ | 1,171 | ​

​

As of March 31, 2025, total future compensation expense related to unvested time-based awards yet to be recognized by the Company was $3,246, which is expected to be recognized over a weighted-average remaining vesting period of approximately 2.59 years. Total unrecognized compensation expense related to unvested performance-based RSU awards was $310, which is expected to be recognized over a weighted-average remaining vesting period of approximately 0.57 years.

19

Table of Contents

9. Net Loss per Share

The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net loss per share for the periods presented due to their antidilutive effect:

​

​ | ​ | ​ | ​ | ​
​ | ​ | March 31,
​ |  | 2025 |  | 2024
Options issued and outstanding |  | 4,344,505 |  | 4,414,105
Restricted stock units issued and outstanding | ​ | 3,574,346 | ​ | 1,196,778
Total |  | 7,918,851 |  | 5,610,883

​

​

​

​

​

​

​

​

​

​

​

​

10. Segment Reporting

Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business in one operating segment related to the development of clinical and preclinical product candidates for neurodegenerative disorders, such as AD and DLB. The Company’s Chief Executive Officer (CEO) serves as the CODM.

The CEO manages and allocates resources to the operations of the Company on a consolidated basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company’s strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, cash forecasting, allocating resources and setting incentive targets. The CEO bases this assessment on the Company’s consolidated net loss. The measure of segment assets is reported on the consolidated balance sheets as total assets.

The table below is a summary of the segment loss, including significant segment expenses (in thousands):

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Three Months Ended March 31,
​ | ​ | 2025 | ​ | 2024
Grant income | ​ | $ | 5,086 | ​ | $ | 4,912
Less: | ​ |  | ​ | ​ |  | ​
Clinical programs | ​ | ​ | 6,877 | ​ | ​ | 6,398
R&D Personnel costs(1) | ​ | ​ | 2,792 | ​ | ​ | 2,626
Preclinical programs | ​ | ​ | 85 | ​ | ​ | 235
Manufacturing | ​ | ​ | 637 | ​ | ​ | 1,004
Other research and development expenses | ​ | ​ | 85 | ​ | ​ | 59
General and administrative expenses(2) | ​ | ​ | 2,713 | ​ | ​ | 2,609
Equity-based compensation | ​ | ​ | 586 | ​ | ​ | 1,171
Other segment items(3) | ​ |  | (209) | ​ |  | (39)
Segment and consolidated net loss | ​ | $ | (8,480) | ​ | $ | (9,151)

​

(1) R&D Personnel costs exclude equity-based compensation

(2) General and administrative expenses exclude equity-based compensation

(3) Other segment items include, Other income, net, Interest expense and Loss on currency translation from liquidation of subsidiary.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

20

Table of Contents

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial conditions and results of operations should be read together with our consolidated financial statements and related notes appearing elsewhere in this Quarterly Report and our audited financial statements and notes thereto as of and for the years ended December 31, 2024 and 2023 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report filed with the Securities and Exchange Commission (“SEC”), on March 20, 2025. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions and other factors that could cause actual results to differ materially from those made, projected or implied in the forward-looking statements. Our actual results may differ materially from those discussed below. Please see “Special Note Regarding Forward-Looking Statements” and “Risk Factors” included in Part I, Item 1A of our Annual Report for factors that could cause or contribute to such differences.

Overview

We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (“CNS”) and retina. Currently available therapies for these diseases are limited, with few Alzheimer’s disease (“AD”) treatments, two approved treatments for geographic atrophy (“GA”) secondary to dry age-related macular degeneration (“dAMD”) and no approved treatments for dementia with Lewy bodies. Our goal is to develop disease-modifying treatments for participants with these degenerative disorders by initially leveraging our expertise in the σ-2 (sigma-2) receptor (“S2R”), which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina. Data indicates that zervimesine antagonizes the binding and toxicity of amyloid beta oligomers via targeting the S2R complex and represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. Clinical results support this hypothesis, and our clinical trial findings provide evidence that the displacement of oligomers from synapses via zervimesine engagement with the S2R results in improved synapse function.

Top-line results from the Phase 2 COG0201 SHINE study were reported in July 2024 with additional data reported in October 2024. SHINE was a randomized, double-blind, placebo-controlled trial that enrolled 153 adults with mild-to-moderate AD. Participants were divided into two zervimesine dose groups (100 mg or 300 mg) and one placebo group, who were dosed daily for six months. Endpoints included safety and biomarker evidence of disease modification as well as cognitive function, as measured by ADAS-Cog 11. SHINE met its primary endpoints of safety and tolerability.

A prespecified analysis conducted on SHINE results identified plasma p-tau217 as a biomarker that may predict an optimal therapeutic response in patients with mild-to-moderate AD. Participants treated with zervimesine (pooled 100 mg and 300 mg) who had baseline levels of plasma p-tau217 below the median of 1.0 pg/mL experienced a 95% reduction of cognitive decline at week 26 as measured by ADAS-Cog 11 relative to placebo-treated participants. P-tau217 is an important biomarker that has shown the ability to distinguish Alzheimer’s disease from other neurodegenerative disorders with a high degree of accuracy compared to other available biomarkers.

In the overall modified intent-to-treat, or mITT, population in SHINE, participants treated with once-daily oral zervimesine experienced less cognitive decline than those treated with placebo. As measured with ADAS-Cog 11, zervimesine-treated participants (pooled 100 mg and 300 mg) experienced a mean 38% slowing of decline at six months versus baseline compared to placebo-treated, but did not achieve statistical significance. There were consistent trends favoring zervimesine in other cognitive measures: ADAS-Cog 13, cognitive composite, MMSE; as well as in functional measures of activities of daily living (ADCS-ADL) and of clinical global impression of change (ADCS-CGIC). No discontinuations due to AEs occurred in the 100 mg zervimesine group. At the 300 mg dose, ten participants (nine at scheduled visits and one at an unscheduled visit) experienced treatment-emergent liver enzyme test (“LFT”) increases (greater than 3xULN) that subsided after cessation of drug without evidence of serious liver injury. There were no LFT elevations observed in the 100 mg dose.

21

Table of Contents

In the overall study population, participants treated zervimesine for six months had reductions in plasma biomarkers associated with Alzheimer’s disease processes compared to placebo participants. Further analysis showed that the individuals with below-median plasma p-Tau217 experienced a pronounced reduction in these key plasma biomarkers compared to placebo. Significant reductions were observed in the level of glial fibrillary acidic protein (GFAP), a protein associated with neuroinflammation. Neurofilament light (NfL), a protein associated with neurodegeneration was also reduced in participants treated with zervimesine compared to placebo. Similarly, amyloid beta (Aβ) and tau species (p-Tau217), which are proteins that build up in patients with Alzheimer’s disease, were lower in participants treated with zervimesine for six months compared to placebo-treated individuals. These findings were presented at the AD/PD™ 2025 Alzheimer's & Parkinson's Diseases Conference in April 2025.

Top-line results from the Phase 2 COG1201 SHIMMER study were presented at the International Lewy Body Dementia Conference (ILBDC) in January 2025. The study enrolled 130 participants who were randomized evenly to one of three dose groups: two treated with once-daily oral zervimesine (100 mg or 300 mg) and one treated with placebo. To be eligible, participants were between 50 and 80 years of age, received a diagnosis of probable DLB, and had a mini-mental state exam, or MMSE, score of between 18 and 27. The study met its primary endpoints of safety and tolerability.

Zervimesine-treated DLB patients scored an average of 86% better than placebo-treated patients on the neuropsychiatric inventory (NPI) A-L at the end of the study. This tool describes the frequency and severity of 12 behavioral symptoms including hallucinations, delusions and anxiety. Compared to placebo-treated participants, those treated with zervimesine performed an average of 52% better on the ADCS-ADL scale, a measure of activities of daily living; an average of 91% better on the CAF, a measure of cognitive fluctuations; an average of 62% better on the Unified Parkinson's Disease Rating Scale (UPDRS) Part III, a measure of motor function such as gait, balance, and tremor.

In 2023 we initiated the Phase 2 COG2201 MAGNIFY study of zervimesine in adults with geographic atrophy secondary to dry AMD. In January 2025, we made the strategic decision to focus our resources on our promising dementia programs in AD and DLB. Therefore, we voluntarily discontinued the MAGNIFY clinical study after 100 of the planned 246 participants were enrolled. The discontinuation was not the result of any safety concerns. MAGNIFY previously passed a masked futility analysis conducted by the contract research organization, or CRO. Results of the analysis, which was conducted on the first 57 participants who completed at least 6 months of dosing, showed that zervimesine-treated patients were experiencing a slower lesion growth rate than those on placebo.

22

Table of Contents

The above Overview covers only the most recently concluded studies in each indication. The following table highlights findings from these and subsequent studies:

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Indication | ​ | Study Identifier | ​ | Clinical Phase | ​ | Status | ​ | Key Findings
Alzheimer’s Disease (AD)
MCI-early | ​ | COG0203 (START) | ​ | Phase 2 | ​ | ongoing | ​ | The study is enrolling up to 540 participants with MCI or early AD ​
mild-moderate | ​ | COG0201 (SHINE) | ​ | Phase 2 (n=153) | ​ | complete | ​ | Participants treated with zervimesine experienced a cognitive benefit compared to placebo ​
mild-moderate | ​ | COG0202 (SEQUEL) | ​ | Phase 2 (n=16) | ​ | complete | ​ | Participants treated with zervimesine exhibited improvement across prespecified EEG parameters ​
mild-moderate | ​ | COG0105 (SPARC) | ​ | Phase 1 (n=23) | ​ | complete | ​ | Treatment with zervimesine was assessed using various imaging modalities, including PET imaging and volumetric MRI (vMRI) ​
mild-moderate | ​ | COG0104 (SNAP) | ​ | Phase 1 (n=3) | ​ | complete | ​ | Confirmed preclinical findings showing an increase in Aβ oligomers in CSF, suggesting increased off-rate from receptors ​
Dementia with Lewy Bodies (DLB)
mild-moderate | ​ | COG1201 (SHIMMER) | ​ | Phase 2 (n=130) | ​ | complete | ​ | Participants treated with zervimesine experienced benefits across behavioral, functional, cognitive and motor scales ​

​

To date, we have funded our operations primarily with proceeds from grants awarded by the National Institute of Aging (the “NIA”), a division of the National Institutes of Health (the “NIH”), and proceeds from our initial public offering (the “IPO”), completed in October 2021, proceeds from our follow-on public offerings, sales of our common stock through our ATM (as defined below), sales of our convertible promissory notes, convertible preferred stock, simple agreements for future equity (“SAFE”) and stock option exercises. Since our inception, we have received approximately $139.5 million in net proceeds from sales of our equity securities, convertible notes, SAFE, stock option exercises, IPO, follow-on public offerings, ATM, and equity line financing with Lincoln Park. As of March 31, 2025, we had cash and cash equivalents of $16.4 million. As of March 31, 2025, we had approximately $47.0 million available from obligated NIA funds for applicable expenses to be incurred in the future.

On December 23, 2022, we entered into a sales agreement with Cantor Fitzgerald & Co. and B. Riley Securities, Inc. (the “Sales Agents”), providing for the offering, issuance and sale by us of up to $40.0 million of our common stock from time to time in “at-the-market” offerings (the “ATM”). For the three months ended March 31, 2025, we sold 2,004,729 shares of common stock pursuant to the ATM for gross proceeds of approximately $1.5 million. As of March 31, 2025, we have approximately $20.4 million remaining in gross proceeds available for future issuances of common stock under the ATM, subject to the limitations of General Instruction I.B.6 of Form S-3.

On March 10, 2023, we entered into a purchase agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”) for an equity line financing (the “Lincoln Park Purchase Agreement”). The Lincoln Park Purchase Agreement provides that, subject to the terms and conditions set forth therein, we have the right, but not the obligation, to direct Lincoln Park to purchase up to $35.0 million of shares of common stock at our sole discretion, over a 36-month period commencing on March 10, 2023. We filed a prospectus supplement to our registration statement on Form S-3 (File No. 333-268992) covering the resale of shares of common stock that are issued under the Lincoln Park Purchase Agreement. During the three months ended March 31, 2025, we did not sell any shares of common stock to Lincoln Park. As of March 31, 2025, $34.8 million was available to draw pursuant to the Lincoln Park Purchase Agreement.

On March 14, 2024, we completed our follow-on public offering, pursuant to which we issued and sold 6,571,428 shares of our common stock at a public offering price of $1.75 per share. On March 28, 2024, the underwriters exercised their option to purchase 985,714 shares of our common stock at a public offering price of $1.75 per share. In connection

23

Table of Contents

with the follow-on public offering, we received net proceeds of approximately $11.9 million, after deducting underwriting discounts and commissions and other offering related expenses.

We expect to continue to incur significant and increasing expenses and net losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel and operate as a public company. We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates. In addition, if we obtain regulatory approval for our product candidates and do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, manufacturing and distribution activities.

As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings, debt financings or other sources, such as potential collaboration agreements and strategic alliances, licensing or similar arrangements with third parties. To the extent available, we expect to continue our pursuit of non-dilutive research contributions, or grants, including additional NIA grant funding. However, we may fail to receive additional NIA grants, or we may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to obtain additional NIA grants or raise capital or enter into such agreements as and when needed could have a material adverse effect on our business, results of operations and financial condition.

Because of the numerous risks and uncertainties associated with product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to raise capital, maintain our research and development efforts, expand our business or continue our operations at planned levels, and as a result we may be forced to substantially reduce or terminate our operations.

We do not own or operate manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of zervimesine for preclinical studies and clinical trials, as well as for commercial manufacture if zervimesine obtains marketing approval. We also rely, and expect to continue to rely, on third parties to manufacture, package, label, store, and distribute zervimesine, if marketing approval is obtained. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment, and personnel while also enabling us to focus our expertise and resources on the development of zervimesine.

Components of Our Results of Operations

Operating Expenses

Research and Development Expenses

Research and development expenses consist primarily of direct and indirect costs incurred for our research activities, including development of our drug discovery efforts and the development of our product candidates. Direct costs include laboratory materials and supplies, contracted research and manufacturing, clinical trial costs, consulting fees, and other expenses incurred to sustain our research and development program. Indirect costs include personnel-related expenses, consisting of employee salaries, related benefits, and stock-based compensation expense for employees engaged in research and development activities, facilities, and other expenses consisting of direct and allocated expenses for rent and depreciation, and lab consumables.

We expense research and development costs as incurred. Non-refundable advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. In-licensing fees and other costs to acquire technologies used in research and development

24

Table of Contents

that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. We track direct costs by stage of program, clinical or preclinical. However, we do not track indirect costs on a program specific basis because these costs are deployed across multiple programs and, as such, are not separately classified.

We cannot reasonably determine the nature, timing, and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. Product candidates in later stages of development generally have higher development costs than those in earlier stages. We expect that our research and development expenses will increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, as our product candidates advance into later stages of development, as we begin to conduct larger clinical trials, as we seek regulatory approvals for any product candidates that successfully complete clinical trials, as we expand our product pipeline, as we maintain, expand, protect and enforce our intellectual property portfolio, and as we incur expenses associated with hiring additional personnel to support our research and development efforts.

General and Administrative Expenses

General and administrative expenses consist primarily of personnel-related costs, including employee salaries, related benefits, and stock-based compensation expense for our employees in the executive, finance and accounting, and other administrative functions. General and administrative expenses also include third-party costs such as legal costs, insurance costs, accounting, auditing and tax related fees, consulting fees and facilities and other expenses not otherwise included as research and development expenses. We expense general and administrative costs as incurred.

We expect that our general and administrative expenses will increase for the foreseeable future as we increase our headcount to support our continued research activities and development of our programs.

Other Income (Expense)

Grant Income

Grant income relates to the grants awarded from governmental bodies that are conditional cost reimbursement grants and are recognized as grant income as allowable costs are incurred and the right to payment is realized. The grants awarded relate to agreed upon direct and indirect costs for specific studies or clinical trials, which may include personnel and consulting costs, costs paid to CROs, research institutions and /or consortiums involved in the grant, as well as facilities and administrative costs. These grants are cost plus fixed fee arrangements in which we are reimbursed for eligible direct and indirect costs over time, up to the maximum amount of each specific grant award. Only costs that are allowable under the grant award, certain government regulations and the NIH’s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. As of March 31, 2025, the Company has been awarded grants with project periods that extend through May 31, 2027, subject to extension. Our clinical trials have been funded by approximately $171.0 million in cumulative grants awarded primarily by the NIA, which includes an approximately $81.0 million grant from the NIA to fund our Phase 2 (COG0203-START) study of zervimesine in patients with early-stage AD, an approximately $30.5 million grant from the NIA to fund our Phase 2 (COG0201-SHINE) study of zervimesine in patients with mild-to-moderate AD, and an approximately $29.5 million grant from the NIA to fund our Phase 2 (COG1201-SHIMMER) study of zervimesine in patients with dementia with Lewy bodies.

Other Income, Net

Other income, net consists primarily of interest income from money market funds, offset partially by other fees such as costs incurred to establish financing opportunities.

25

Table of Contents

Interest Expense

Interest expense for the three months ended March 31, 2025 and 2024 consisted of interest expense related to the insurance premium financing arrangement with a lender.

Results of Operations

Comparison of the Three Months Ended March 31, 2025 and 2024

The following table summarizes our results of operations (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, | ​ | ​ | ​
​ |  | 2025 |  | 2024 |  | Change
Operating Expenses: |  | ​ |  |  | ​ |  |  | ​ |
Research and development | ​ | $ | 10,786 | ​ | $ | 10,553 | ​ | $ | 233
General and administrative | ​ |  | 2,989 | ​ |  | 3,549 | ​ |  | (560)
Total operating expenses | ​ |  | 13,775 | ​ |  | 14,102 | ​ |  | (327)
Loss from operations | ​ |  | (13,775) | ​ |  | (14,102) | ​ |  | 327
Other income (expense): | ​ |  |  | ​ |  |  | ​ |  | ​
Grant income | ​ |  | 5,086 | ​ |  | 4,912 | ​ |  | 174
Other income, net | ​ |  | 214 | ​ |  | 244 | ​ |  | (30)
Interest expense | ​ | ​ | (5) | ​ | ​ | (10) | ​ | ​ | 5
Loss on currency translation from liquidation of subsidiary | ​ |  | — | ​ |  | (195) | ​ |  | 195
Total other income, net | ​ |  | 5,295 | ​ |  | 4,951 | ​ |  | 344
Net loss | ​ | $ | (8,480) | ​ | $ | (9,151) | ​ | $ | 671

​

Research and Development Expenses

The following table summarizes our research and development expenses (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, | ​ | ​ | ​
​ |  | 2025 |  | 2024 |  | Change
Clinical programs | ​ | $ | 6,877 | ​ | $ | 6,398 | ​ | $ | 479
Personnel |  | ​ | 3,102 |  | ​ | 2,857 |  | ​ | 245
Manufacturing |  | ​ | 637 |  | ​ | 1,004 |  | ​ | (367)
Preclinical programs |  | ​ | 85 |  | ​ | 235 |  | ​ | (150)
Other expense |  | ​ | 85 |  | ​ | 59 |  | ​ | 26
​ | ​ | $ | 10,786 | ​ | $ | 10,553 | ​ | $ | 233

​

Research and development expenses were $10.8 million for the three months ended March 31, 2025, compared to $10.6 million for the three months ended March 31, 2024. The increase of $0.2 million was primarily due to the following:

| ● | an increase of $0.5 million in clinical programs primarily related to increased Phase 2 trial activities with contract research organizations;

| ● | an increase of $0.2 million in personnel costs related to increases in year over year employee compensation and benefits;

| ● | a decrease of $0.4 million in manufacturing related to lower costs with contract manufacturing organizations for the replenishment of clinical trial supply; and

| ● | a decrease of $0.1 million in preclinical programs and other expenses primarily due to decreased research activities.

26

Table of Contents

General and Administrative Expenses

General and administrative expenses were $3.0 million for the three months ended March 31, 2025, compared to $3.5 million for the three months ended March 31, 2024. The change in general and administrative expenses was driven primarily by a decrease in stock compensation, which was partially offset by an increase in professional fees.

Other Income (Expense)

Grant Income

Grant income was $5.1 million for the three months ended March 31, 2025, compared to $4.9 million for the three months ended March 31, 2024. The change in grant income is correlated with the increase in eligible reimbursable costs related to clinical trials incurred during 2025 as compared to 2024.

Other Income, Net

Other income, net was $0.2 million for the three months ended March 31, 2025, compared to other income, net of $0.2 million for the three months ended March 31, 2024. The change in other income, net was insignificant period over period.

Interest Expense

Interest expense was less than $0.1 million for the three months ended March 31, 2025, compared to interest expense of less than $0.1 million for the three months ended March 31, 2024. Interest expense was not significant in either period.

Liquidity and Capital Resources

Sources of Liquidity

To date, we have funded our operations primarily with proceeds from grants awarded by the NIA, and proceeds from the sales of our convertible promissory notes, convertible preferred stock, SAFE, stock option exercises, follow-on equity offerings, sales under our ATM and equity line financing, and our IPO. Since our inception, we have been awarded grant awards primarily from the NIA in the aggregate amount of approximately $171.0 million and have raised approximately $139.5 million in net proceeds from sales of our equity securities, convertible notes and SAFE, stock option exercises, our ATM, our equity line financing with Lincoln Park, our IPO and our follow-on public offering. The net proceeds from our IPO, which closed on October 13, 2021, were approximately $44.2 million, after deducting underwriting discounts and commissions and other offering related expenses payable by us. On November 15, 2022, we closed our follow-on public offering, selling 5,000,000 shares of our common stock at a public offering price of $1.20 per share. The net proceeds were approximately $5.2 million, after deducting underwriting discounts and commissions and other offering related expenses payable by us. On December 23, 2022, we entered into a sales agreement with the Sales Agents, providing for the offering, issuance and sale by us of up to $40.0 million of our common stock from time to time in ATM offerings. As of March 31, 2025, we sold 24,776,992 shares of common stock under the ATM for gross proceeds of approximately $19.6 million. As of March 31, 2025, there was $20.4 million of common stock remaining available for sale under the ATM, subject to the limitations of General Instruction I.B.6 of Form S-3. In addition, in March 2023, we entered into the Lincoln Park Purchase Agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park, giving the Company the right, but not the obligation to sell to Lincoln Park up to $35.0 million worth of shares of our common stock. As of March 31, 2025, we sold 125,000 shares of common stock to Lincoln Park for proceeds of $0.2 million, as part of the equity line financing arrangement. As of March 31, 2025, $34.8 million was available to draw pursuant to the Lincoln Park Purchase Agreement. On March 14, 2024, we closed a follow-on public offering of 6,571,428 shares of our common stock at a public offering price of $1.75 per share. As part of the follow-on offering, the underwriters exercised their option to purchase 985,714 shares of our common stock on March 28, 2024, at a public offering price of $1.75 per share. The net proceeds were approximately $11.9 million, after deducting underwriting discounts and commissions and other offering related expenses payable by us.

27

Table of Contents

As of March 31, 2025, we had $16.4 million in cash and cash equivalents and have not generated positive cash flows from operations. Based on our current business plans, we believe that our existing cash and cash equivalents, income from non-dilutive grants, and net proceeds from our March 2024 follow-on public offering will be sufficient for us to fund our operating expenses and capital expenditures requirements into the fourth quarter of 2025, which assumes no usage from the remaining ATM nor the Lincoln Park Purchase Agreement. We have based these estimates on assumptions that may prove to be incorrect or require adjustment as a result of business decisions, and we could utilize our available capital resources sooner than we currently expect.

Future Funding Requirements

We expect to continue to incur significant and increasing expenses and net losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel, and operate as a public company. We anticipate that we will need to raise additional funding in the future to fund our operations, including the commercialization of any approved product candidates. We are subject to the risks typically related to the development of new products, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business.

Our future funding requirements will depend on many factors, including, but not limited to:

| ● | the scope, progress, costs and results of our ongoing and planned clinical trials of zervimesine, as well as the associated costs, including any unforeseen costs we may incur as a result of preclinical study or clinical trial delays due to a pandemic, such as the COVID-19 pandemic or other diseases, macroeconomic conditions, global or political instability, such as the ongoing global and regional conflicts, inflation, or other delays;

| ● | the scope, progress, costs and results of preclinical development, laboratory testing and clinical trials for any future product candidates we may decide to pursue;

| ● | the extent to which we develop, in-license or acquire other product candidates and technologies;

| ● | the costs and timing of process development and manufacturing scale-up activities associated with our product candidates and other programs as we advance them through preclinical and clinical development;

| ● | the availability, timing, and receipt of any future NIA grants, or any changes to our grants based on political or regulatory pressures;

| ● | the number and development requirements of other product candidates that we may pursue;

| ● | the costs, timing and outcome of regulatory review of our product candidates;

| ● | the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;

| ● | the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;

| ● | our ability to establish collaborations to commercialize zervimesine or any of our other product candidates outside the United States;

| ● | the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and

28

Table of Contents

| ● | the additional costs we may incur as a result of operating as a public company, including our efforts to enhance operational systems and hire additional personnel, including enhanced internal controls over financial reporting.

Until such time as we can generate significant revenue from product sales, we expect to finance our operations through a combination of public or private equity offerings, debt financings or other sources, such as potential collaboration agreements and strategic alliances, licensing or similar arrangements with third parties. To the extent available, we expect to continue our pursuit of non-dilutive research contributions, or grants, including additional NIA grant funding. However, we may fail to receive additional NIA grants, or we may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to obtain additional NIA grants or raise capital or enter into such agreements as and when needed could have a material adverse effect on our business, results of operations and financial condition.

To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, licenses and other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. Adequate funding may not be available when needed or on terms acceptable to us, or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the effects of the COVID-19 pandemic or other diseases, the ongoing global and regional conflicts, inflation, liquidity constraints, failures and instability in U.S. and international financial banking systems, and otherwise. If we fail to obtain necessary capital when needed on acceptable terms, or at all, it could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. Insufficient liquidity may also require us to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. We cannot assure you that we will ever be profitable or generate positive cash flows from operating activities.

Cash Flows

The following table summarizes our cash flows for the periods indicated (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31,
​ |  | 2025 |  | 2024
Cash flows used in operating activities | ​ | $ | (9,877) |  | $ | (7,244)
Cash flows used in investing activities | ​ |  | — | ​ |  | —
Cash flows provided by financing activities | ​ |  | 1,296 | ​ |  | 11,993
Net (decrease) increase in cash and cash equivalents | ​ | $ | (8,581) | ​ | $ | 4,749

​

Cash used in operating activities

Net cash used in operating activities for the three months ended March 31, 2025 and 2024 was $9.9 million and $7.2 million, respectively. The change in cash used in operating activities of $2.6 million was driven by an increase in operating assets and liabilities of $2.5 million, primarily due to an increase in grant receivables of $2.5 million, combined with decreases in non-cash adjustments of $0.8 million, primarily due to a decrease in equity-based compensation of $0.6 million, for the three months ended March 31, 2025.

Cash used in investing activities

During the three months ended March 31, 2025 and 2024, no cash was used in or provided by investing activities.

29

Table of Contents

Cash provided by financing activities

Net cash provided by financing activities was $1.3 million and $12.0 million for the three months ended March 31, 2025 and 2024, respectively. The change in net cash provided by financing activities is primarily related to net proceeds from the issuance of common stock in our follow-on offering in March 2024 and under the ATM program.

Contractual Obligations

The following table summarizes our contractual obligations as of March 31, 2025 (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Less than | ​ | 1 to 3 | ​ | 3 to 5 | ​ | More than 5 | ​ | ​ | ​
​ |  | 1 Year |  | Years |  | Years |  | years |  | Total
Operating lease obligations | ​ | $ | 223 | ​ | $ | 208 | ​ | $ | 104 | ​ | $ | — | ​ | $ | 535
Other obligations | ​ | ​ | 161 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 161
Total: | ​ | $ | 384 | ​ | $ | 208 | ​ | $ | 104 | ​ | $ | — | ​ | $ | 696

​

In October 2023, we entered into an insurance premium financing arrangement with a lender whereby we financed $0.7 million of certain premiums at a 8.65% annual interest rate. Payments of less than $0.1 million are due monthly from November 2023 through October 2024. As of December 31, 2024, there was no outstanding balance on the loan.

In October 2024, we entered into an insurance premium financing arrangement whereby we financed $0.4 million of certain premiums at a 8.65% annual interest rate. Payments of less than $0.1 million are due monthly from November 2024 through July 2025. As of March 31, 2025, the outstanding principal of the loan was $0.2 million.

We have entered into an operating leases for office and laboratory facilities under agreements that run through May 31, 2029. The amounts reflected in the table above consist of the future minimum lease payments under the non-cancelable lease arrangements.

On August 31, 2022, we entered into an agreement to lease 2,980 square feet of office space in Pittsburgh, Pennsylvania. The lease has a term of 45 months and commenced on October 1, 2022. The annual base rent under the lease is less than $0.1 million throughout the term of the lease. Total payments due over the term of the lease are $0.2 million. Additionally, on August 31, 2022, we modified one of our existing lease agreements with the landlord for approximately 3,706 square feet of lab space at the same location to extend the lease term termination date from June 30, 2023 until June 30, 2026.

On July 1, 2021, we entered into an agreement to lease 2,864 square feet of office space in Purchase, New York. The lease has a term of 89 months and commenced on December 9, 2021. The annual base rent under the lease is less than $0.1 million for the first lease year and is subject to annual increases of between 1.82% and 2.04%. We provided a security deposit in the form of a Letter of Credit in the amount of less than $0.1 million pursuant to the terms of the lease.

We enter into contracts in the normal course of business with CROs and other vendors to assist in the performance of our research and development and other services and products for operating purposes. These contracts typically do not contain minimum purchase commitments and generally provide for termination on notice, and therefore are cancelable contracts and not included in the table of contractual obligations.

Critical Accounting Policies and Use of Estimates

The Critical Accounting Policies and Significant Judgements and Estimates included in our Annual Report on Form 10-K have not materially changed. See “Critical Accounting Policies and Use of Estimates” included in Part II, Item 7 of our Annual Report on Form 10-K filed with the SEC on March 20, 2025.

30

Table of Contents

Recent Accounting Pronouncements

For a description of recent accounting pronouncements, see Note 2 of the notes to our consolidated financial statements included in this Quarterly Report.

Emerging Growth Company Status

We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (1) are no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

We will remain an emerging growth company until the earliest to occur of: (1) the last day of the fiscal year in which we have at least $1.235 billion in annual revenue; (2) the last day of the fiscal year in which we are deemed to be a “large accelerated filer,” as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year; (3) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period; and (4) the last day of the fiscal year ending after the fifth anniversary of our IPO.

Item 3.Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company,” as that term is defined in Rule 229.10(f)(1), we are not required to provide the information required by this Item.

Item 4.Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our President and Chief Executive Officer and our Chief Financial Officer have evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act) as of the end of the period covered by this Quarterly Report. Based on this evaluation, our President and Chief Executive Officer and our Chief Financial Officer concluded that, as of the end of the period covered by this Quarterly Report, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our President and Chief Executive Officer and our Chief Financial Officer, to allow for timely decisions regarding required disclosures, and recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Management’s Report on Internal Controls over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including our President and Chief Executive Officer and our Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting. Management has used the framework set forth in the report entitled “Internal Control—Integrated Framework (2013)” published by the Committee of Sponsoring Organizations of the Treadway Commission to evaluate the effectiveness of our internal control over financial reporting. Based on its evaluation, management has concluded that our internal control over financial reporting was effective as of March 31, 2025.

31

Table of Contents

Changes in Internal Control

There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including our President and Chief Executive Officer and our Chief Financial Officer, does not expect that our disclosure controls and procedures or internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the system are met and cannot detect all deviations. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or deviations, if any, within the company have been detected. Projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

​

32

Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We are not aware of any pending legal actions that would, if determined adversely to us, have a material adverse effect on our business and operations.

We may, from time to time, become involved in disputes and proceedings arising in the ordinary course of business. In addition, as a public company, we are also potentially susceptible to litigation, such as claims asserting violations of securities laws. Any such claims, with or without merit, if not resolved, could be time-consuming and result in costly litigation. There can be no assurance that an adverse result in any future proceeding would not have a potentially material adverse effect on our business, results of operations, and financial condition.

Item 1A. Risk Factors

You should carefully consider the risk factors described in our Annual Report under the caption “Item 1A. “Risk Factors.” Other than as set forth below, there have been no material changes in our risk factors included in our Annual Report. The risks described in our Annual Report are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.

Changes in funding for, or disruptions to the staffing and operations of the FDA and other government agencies could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.

Currently, federal agencies in the U.S. are operating under a continuing resolution that is set to expire on September 30, 2025. Without appropriation of additional funding to federal agencies, our business operations related to our product development activities for the U.S. market could be impacted. The ability of the FDA to review and/or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA’s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA’s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other federal agencies, including substantial leadership departures, personnel cuts, and policy changes, may also slow the time necessary for new drugs to be reviewed and/or approved, which would harm our business. Changes and cuts in FDA staffing also could result in delays in the FDA’s responsiveness or in its ability to review IND submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion or at all.

A prolonged government shutdown or significant leadership, personnel, and/or policy changes, or other substantial modification in agency activities (including due to global health concerns or geopolitical factors) could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. In addition, government funding of other agencies on which our operations may rely, including those that fund research and development activities and clinical trials, is subject to the political process, which is inherently fluid and unpredictable. Disruptions at agencies that fund our research and development activities and our clinical trials, or changes to such agencies’ budgets, may negatively impact our operations and ongoing clinical trials and may limit our ability to seek additional funding in the future. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets.

With the change in the U.S. presidential administration in 2025, there is substantial uncertainty as to whether and how the Trump administration will seek to modify or revise the requirements and policies of the FDA and other regulatory

33

Table of Contents

agencies with jurisdiction over our product candidates and any products for which we obtain approval. This uncertainty could present new challenges and/or opportunities as we navigate development and approval of our product candidates. Additionally, the new administration could issue or promulgate executive orders, regulations, policies or guidance that adversely affect us or create a more challenging or costly environment to pursue the development of new therapeutic candidates.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Recent Sales of Unregistered Securities

There were no unregistered sales of our equity securities during the fiscal quarter ended March 31, 2025.

Repurchase of Shares of Company Equity Securities

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

34

Table of Contents

Item 6. Exhibits

Exhibit |  |  |  | Incorporated by Reference |  | Filed
Number |  | Exhibit Description |  | Form |  | File No. |  | Exhibit |  | Filing Date |  | Herewith
3.1 | ​ | Third Amended and Restated Certificate of Incorporation of Cognition Therapeutics, Inc. | ​ | 8-K | ​ | 001-40886 | ​ | 3.1 | ​ | 10/14/2021 | ​ | ​
3.2 | ​ | Second Amended and Restated Bylaws of Cognition Therapeutics, Inc. | ​ | 10-Q | ​ | 001-40886 | ​ | 3.1 | ​ | 05/04/2023 | ​ | ​
3.3 | ​ | Amendment to the Second Amended and Restated Bylaws of Cognition Therapeutics, Inc. | ​ | 10-K | ​ | 001-40886 | ​ | 3.3 | ​ | 03/20/2025 | ​ | ​
31.1 |  | Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X
31.2 |  | Certification of Principal Financial and Accounting Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X
32.1* |  | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X
32.2* |  | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X
101.INS |  | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |  |  |  |  |  |  |  |  |  | X
101.SCH |  | Inline XBRL Taxonomy Extension Schema Document |  |  |  |  |  |  |  |  |  | X
101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document |  |  |  |  |  |  |  |  |  | X
101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document |  |  |  |  |  |  |  |  |  | X
101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document |  |  |  |  |  |  |  |  |  | X
101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document |  |  |  |  |  |  |  |  |  | X
104 | ​ | Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101). | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | X

​

* This certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

​

35

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| Cognition Therapeutics, Inc.
Date: May 7, 2025 | By: | /s/ Lisa Ricciardi
|  | Lisa Ricciardi
|  | Chief Executive Officer, President and Director (Principal Executive Officer)
Date: May 7, 2025 | By: | /s/ John Doyle
|  | John Doyle
|  | Chief Financial Officer (Principal Financial and Accounting Officer)

​

​

​

36